Patents Examined by Lexington Hoffman
-
Patent number: 7179805Abstract: The present invention relates to compounds having a structure according to Formula I wherein n, m, z, R, R2, R3, R4, R5, R6, A, E, X, Y, a and b are as defined above; or an optical isomer, diastereomer or enantiomer thereof; a pharmaceutically acceptable salt, hydrate, or prodrug thereof.Type: GrantFiled: September 9, 2004Date of Patent: February 20, 2007Assignee: Janssen Pharmaceutica N.V.Inventors: Eugene B. Grant, III, Mark J. Macielag, Xiaoqing Xu, Steven David Paget, Michele Ann Weidner-Wells
-
Patent number: 7176198Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which ?7 is known to be involved.Type: GrantFiled: July 25, 2003Date of Patent: February 13, 2007Assignee: Pfizer Inc.Inventors: David W. Piotrowski, Eric Jon Jacobsen, Brad A. Acker, Daniel Patrick Walker, Donn G. Wishka, Vincent E. Groppi, Jr.
-
Patent number: 7169787Abstract: The invention relates to new 7-azaindoles, their use as inhibitors of phosphodiesterase 4 and to methods for their synthesis.Type: GrantFiled: October 25, 2001Date of Patent: January 30, 2007Assignee: Elbion AGInventors: Norbert Höfgen, Ute Egerland, Thomas Kronbach, Degenhard Marx, Stefan Szelenyi, Hildegard Kuss, Emmanuel Polymeropoulos
-
Patent number: 7094788Abstract: The present invention relates to new compounds of general formula 1 wherein X? and the groups A, B, R, R1, R2, R3, R3?, R4, R4?, Rx and Rx? may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharmaceutical compositions.Type: GrantFiled: March 25, 2003Date of Patent: August 22, 2006Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Matthias Grauert, Michael P. Pieper, Gerald Pohl, Georg Speck, Steffen Breitfelder
-
Patent number: 7081531Abstract: Compounds having the formula (I), Ar—(F)-(E)-(CR3R4)—(CHR5)m-(T)-(Q)-Ar1, are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar1 are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is —C(?O)N(R10)—, —SO2N(R10)—, —N(R11)C(?O)N(R10)—, —N(R11)SO2N(R10)—, —N(R11)C(?S)N(R10)—, —N(R11)C(?O)—, —N(R11)SO2—, —N(R12)C(?O)CH(R13)—, or CH(R13)C(?O)N(R12)—; Q is —C(?O)— or C1-2alkylene; and R3, R4, R5, R9, R10, R11, R12, and R13 are defined as set forth in the specification.Type: GrantFiled: February 26, 2004Date of Patent: July 25, 2006Assignee: Roche Palo Alto LLCInventor: Leyi Gong
-
Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
Patent number: 7071207Abstract: This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.Type: GrantFiled: September 24, 2002Date of Patent: July 4, 2006Assignee: Bayer Pharmaceuticals CorporationInventors: Roger A. Smith, Stephen J. O'Connor, Wai C. Wong, Soongyu Choi, Harold C. Kluender, Jianmei Fan, Zhonghua Zhang, Rico C. Lavoie, Brent L. Podlogar -
Patent number: 7067553Abstract: The present invention relates to thiourea compounds and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as an antagonist against vanilloid receptor (VR) and the pharmaceutical compositions thereof. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.Type: GrantFiled: August 20, 2001Date of Patent: June 27, 2006Assignee: Pacific CorporationInventors: Young Ger Suh, Uh Taek Oh, Hee Doo Kim, Jee Woo Lee, Hyeung Geun Park, Young Ho Park, Jung Bum Yi
-
Patent number: 7053107Abstract: Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.Type: GrantFiled: December 15, 2003Date of Patent: May 30, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Allen J. Borchardt, Robert Steven Kania, Cynthia L. Palmer
-
Patent number: 7015231Abstract: The present invention is related to aza-oxindole derivatives, compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.Type: GrantFiled: September 24, 2002Date of Patent: March 21, 2006Assignee: SmithKline Beecham CorporationInventors: Karen Elizabeth Lackey, Edgar Raymond Wood, III
-
Patent number: 6992080Abstract: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.Type: GrantFiled: September 17, 2003Date of Patent: January 31, 2006Assignee: Schering CorporationInventors: Michael P. Dwyer, Timothy J. Guzi, Kamil Paruch, Ronald J. Doll, Kartik M. Keertikar, Viyyoor M. Girijavallabhan